Skip to main content

Table 1 per protocol analysis

From: Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab

  ASAS20 ASAS40
Wk. PLC ADA p PLC ADA p
4 4 (31%) 9 (56%) 0.24 3 (23%) 7 (44%) 0.19
8 3 (23%) 10 (63%) 0.03* 3 (23%) 9 (56%) 0.07
12 4 (31%) 9 (63%) 0.17 4 (31) 9 (56%) 0.17